NGENLA

Clinical safety rating: caution

Comprehensive clinical and safety monograph for NGENLA (NGENLA).

How it works

NGENLA (somapacitan) is a long-acting recombinant human growth hormone analog. It binds to growth hormone receptors, activating JAK2/STAT5 signaling pathways, leading to increased IGF-1 production and linear growth.

What the body does with it

Metabolism	Metabolized by proteolytic degradation into smaller peptides and amino acids.
Excretion	Primarily renal elimination via glomerular filtration and tubular catabolism; <1% excreted unchanged in urine.
Half-life	Terminal elimination half-life approximately 19 hours (range 15–23 hours) following subcutaneous administration, supporting once-daily dosing.
Protein binding	Approximately 80–90% bound to insulin-like growth factor binding proteins (IGFBPs), primarily IGFBP-3.
Volume of Distribution	Vd approximately 0.4 L/kg, suggesting distribution into extracellular fluid and well-perfused tissues.
Bioavailability	Subcutaneous: 90–100% (absolute bioavailability); other routes not clinically utilized.
Onset of Action	Subcutaneous: Elevation of serum insulin-like growth factor 1 (IGF-1) levels detectable within 4–6 hours post-dose.
Duration of Action	Duration of action approximately 24 hours, with sustained IGF-1 levels over the dosing interval; requires daily administration.

Classification & Brands

Dosing & administration

0.24 mg/kg subcutaneously once weekly

Dosage form	INJECTABLE
Renal impairment	No dose adjustment required for mild to moderate renal impairment (eGFR >=30 mL/min/1.73 m2). Not recommended in severe renal impairment (eGFR <30 mL/min/1.73 m2) due to lack of data.
Liver impairment	No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh Class A or B). Not studied in severe hepatic impairment (Child-Pugh Class C).
Pediatric use	0.10 mg/kg subcutaneously once weekly, titrated by 0.04 mg/kg every 4–6 weeks based on growth response, maximum 0.24 mg/kg once weekly.
Geriatric use	No specific dose adjustment. Use with caution due to potential for age-related renal impairment and increased risk of adverse effects.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for NGENLA (NGENLA).

Breastfeeding	Not known if excreted in human milk. Endogenous growth hormone is present in breast milk. M/P ratio unknown. Caution advised; consider risk-benefit.
Teratogenic Risk	No adequate human data; animal studies show no teratogenicity at clinically relevant doses. Use only if clearly needed during pregnancy. First trimester: unknown risk; Second/Third trimester: no documented fetal harm from growth hormone exposure.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

No FDA black box warning.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to somapacitan or any excipients","Active malignancy","Acute critical illness (e.g., open heart surgery, abdominal surgery, multiple trauma, or respiratory failure)"]

Clinical Precautions

Precautions

["Increased risk of neoplasms","Benign intracranial hypertension (pseudotumor cerebri)","Fluid retention (edema, arthralgia, carpal tunnel syndrome)","Hypersensitivity reactions","Endocrine disorders (hypothyroidism, adrenal insufficiency)","Slipped capital femoral epiphysis","Pancreatitis"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

NGENLA

Clinical safety rating: caution

Comprehensive clinical and safety monograph for NGENLA (NGENLA).

How it works

What the body does with it

Metabolism	Metabolized by proteolytic degradation into smaller peptides and amino acids.
Excretion	Primarily renal elimination via glomerular filtration and tubular catabolism; <1% excreted unchanged in urine.
Half-life	Terminal elimination half-life approximately 19 hours (range 15–23 hours) following subcutaneous administration, supporting once-daily dosing.
Protein binding	Approximately 80–90% bound to insulin-like growth factor binding proteins (IGFBPs), primarily IGFBP-3.
Volume of Distribution	Vd approximately 0.4 L/kg, suggesting distribution into extracellular fluid and well-perfused tissues.
Bioavailability	Subcutaneous: 90–100% (absolute bioavailability); other routes not clinically utilized.
Onset of Action	Subcutaneous: Elevation of serum insulin-like growth factor 1 (IGF-1) levels detectable within 4–6 hours post-dose.
Duration of Action	Duration of action approximately 24 hours, with sustained IGF-1 levels over the dosing interval; requires daily administration.

Classification & Brands

Dosing & administration

0.24 mg/kg subcutaneously once weekly

Dosage form	INJECTABLE
Renal impairment	No dose adjustment required for mild to moderate renal impairment (eGFR >=30 mL/min/1.73 m2). Not recommended in severe renal impairment (eGFR <30 mL/min/1.73 m2) due to lack of data.
Liver impairment	No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh Class A or B). Not studied in severe hepatic impairment (Child-Pugh Class C).
Pediatric use	0.10 mg/kg subcutaneously once weekly, titrated by 0.04 mg/kg every 4–6 weeks based on growth response, maximum 0.24 mg/kg once weekly.
Geriatric use	No specific dose adjustment. Use with caution due to potential for age-related renal impairment and increased risk of adverse effects.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for NGENLA (NGENLA).

Breastfeeding	Not known if excreted in human milk. Endogenous growth hormone is present in breast milk. M/P ratio unknown. Caution advised; consider risk-benefit.
Teratogenic Risk	No adequate human data; animal studies show no teratogenicity at clinically relevant doses. Use only if clearly needed during pregnancy. First trimester: unknown risk; Second/Third trimester: no documented fetal harm from growth hormone exposure.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

No FDA black box warning.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to somapacitan or any excipients","Active malignancy","Acute critical illness (e.g., open heart surgery, abdominal surgery, multiple trauma, or respiratory failure)"]